MMIP briefing paper: The fiscal benefits of establishing and retaining medicine manufacture in the UK
This paper highlights the factors which combine to make the UK one of the most competitive tax and fiscal frameworks globally for medicines manufacture and in the top tier of the G20. This is not widely recognised here in the UK or overseas and the purpose of this paper is to start to address this lack of awareness by setting out the UK proposition in a simple summary.
BIA’s influence and connect were out in force last week – grasping a timely opportunity to get our key Autumn Budget asks across impactfully to the Chancellor with the clear backing of over 200 member CEOs, and putting on a dynamic, pro-innovation Future of UK Regulation conference, featuring MHRA and NICE CEOs amongst other key stakeholders.
In this blog, Chris Sadler, Development Lead at Astrea Bioseparations Ltd, explores how combining multiple interaction mechanisms in chromatography can unlock new, cost-effective solutions for complex downstream challenges.
This blog explores the transformative BIA MAC Leadership Programme (LeaP) — a unique initiative empowering emerging bioprocessing professionals to accelerate their careers and strengthen leadership across the UK life sciences sector. With 76% of participants reporting career progression, LeaP is shaping the next generation of biotech leaders.
LifeArc and the Gates Foundation are funding seven ground-breaking new projects launched to lower the cost of monoclonal antibody production to make them more accessible globally.
From scaling up advanced therapy manufacturing to harnessing the power of digital and automation, Ed Samuel, the new COO of the CGT Catapult, discusses how collaboration and innovation will shape the next phase of the UK’s cell and gene therapy ecosystem.
